Search
- Jun 10
Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval
Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...
- Jun 3, 2023
Modality profile: Oncolytic Immunotherapies at #ASCO23
Replimune Founder and Head of R&D Robert Coffin describes the oncolytic immunotherapy approach to cancer research.